| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Margaret Dugan | Chief Medical Officer | 2025-10-16 | 1,395 | $21.07 | $29.39kSell |
| Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 3,345 | $2.92 | $9.77kBuy |
| Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 8,378 | $25.11 | $210.39kSell |
| Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 5,000 | $25.11 | $125.56kSell |
| Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 3,345 | $25.00 | $83.63kSell |
| Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 13,378 | $3.22 | $43.08kBuy |
| Jenny Herman | SVP Controller | 2025-03-06 | 666 | $21.11 | $14.06kSell |
| Geoffrey Craig Porges | EVP CFO | 2025-03-03 | 5,491 | $21.76 | $119.48kSell |
| Yvonne Tran | EVP CLO CPO | 2025-02-18 | 3,902 | $4.34 | $16.93kBuy |
| Yvonne Tran | EVP CLO CPO | 2025-02-18 | 3,902 | $28.00 | $109.26kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Blackrock Inc | 12.98% | 9,561,139 | $167.89M | Institution |
| Melinda Gates Foundation Trust Bill | 9.48% | 6,981,664 | $122.60M | Insider |
| Gates Foundation Trust | 9.48% | 6,981,664 | $122.60M | Institution |
| Vanguard Group Inc | 8.61% | 6,339,077 | $111.31M | Institution |
| David E. Shaw | 8.41% | 6,196,609 | $108.81M | Insider |
| Rubric Capital Management LP | 7.15% | 5,268,817 | $92.52M | Institution |
| Sumitomo Mitsui Trust Group Inc | 6.18% | 4,554,569 | $79.98M | Institution |
| Ubs Am A Distinct Business Unit Of Ubs Asset Management Americas LLC | 4.48% | 3,303,659 | $58.01M | Institution |
| Amova Asset Management Americas Inc | 3.58% | 2,638,935 | $46.34M | Institution |
| Lazard Asset Management LLC | 3.19% | 2,346,441 | $41.20M | Institution |